Ironwood Pharmaceuticals, Inc.
IRWD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $122 | $85 | $41 | $91 |
| % Growth | 43.2% | 107.2% | -54.6% | – |
| Cost of Goods Sold | $0 | $0 | $27 | $0 |
| Gross Profit | $122 | $85 | $14 | $91 |
| % Margin | 100% | 100% | 33.3% | 100% |
| R&D Expenses | $22 | $23 | $27 | $25 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $22 | $17 | $0 | $34 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | -$0 | $15 | $0 |
| Operating Expenses | $47 | $40 | $43 | $59 |
| Operating Income | $75 | $45 | -$29 | $31 |
| % Margin | 61.8% | 53.2% | -70.7% | 34.8% |
| Other Income/Exp. Net | -$7 | -$7 | -$7 | -$7 |
| Pre-Tax Income | $68 | $38 | -$36 | $24 |
| Tax Expense | $28 | $14 | $1 | $22 |
| Net Income | $40 | $24 | -$37 | $2 |
| % Margin | 32.8% | 27.7% | -90.9% | 2.5% |
| EPS | 0.25 | 0.15 | -0.23 | 0.014 |
| % Growth | 66.7% | 165.2% | -1,731.2% | – |
| EPS Diluted | 0.23 | 0.14 | -0.23 | 0.014 |
| Weighted Avg Shares Out | 162 | 162 | 161 | 160 |
| Weighted Avg Shares Out Dil | 178 | 162 | 161 | 160 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $8 | $8 | $8 | $9 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $77 | $47 | -$10 | $33 |
| % Margin | 63% | 54.7% | -24.5% | 36.9% |